148 related articles for article (PubMed ID: 19787208)
1. Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review).
Muraki Y; Banno K; Yanokura M; Kobayashi Y; Kawaguchi M; Nomura H; Hirasawa A; Susumu N; Aoki D
Oncol Rep; 2009 Nov; 22(5):967-72. PubMed ID: 19787208
[TBL] [Abstract][Full Text] [Related]
2. Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer.
Banno K; Yanokura M; Susumu N; Kawaguchi M; Hirao N; Hirasawa A; Tsukazaki K; Aoki D
Oncol Rep; 2006 Dec; 16(6):1189-96. PubMed ID: 17089036
[TBL] [Abstract][Full Text] [Related]
3. Carcinogenic mechanisms of endometrial cancer: involvement of genetics and epigenetics.
Banno K; Yanokura M; Iida M; Masuda K; Aoki D
J Obstet Gynaecol Res; 2014 Aug; 40(8):1957-67. PubMed ID: 25131761
[TBL] [Abstract][Full Text] [Related]
4. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D
Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476
[TBL] [Abstract][Full Text] [Related]
5. Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability.
Kondo E; Furukawa T; Yoshinaga K; Kijima H; Semba S; Yatsuoka T; Yokoyama T; Fukushige S; Horii A
Int J Oncol; 2000 Sep; 17(3):535-41. PubMed ID: 10938395
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation in the p16 promoter region in the carcinogenesis of endometrial cancer in Japanese patients.
Yanokura M; Banno K; Susumu N; Kawaguchi M; Kuwabara Y; Tsukazaki K; Aoki D
Anticancer Res; 2006; 26(2A):851-6. PubMed ID: 16619479
[TBL] [Abstract][Full Text] [Related]
8. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer.
Kawaguchi M; Yanokura M; Banno K; Kobayashi Y; Kuwabara Y; Kobayashi M; Nomura H; Hirasawa A; Susumu N; Aoki D
Int J Oncol; 2009 Jun; 34(6):1541-7. PubMed ID: 19424571
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.
Liao X; Siu MK; Chan KY; Wong ES; Ngan HY; Chan QK; Li AS; Khoo US; Cheung AN
Int J Cancer; 2008 Jul; 123(2):296-302. PubMed ID: 18404674
[TBL] [Abstract][Full Text] [Related]
10. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers.
Kanaya T; Kyo S; Maida Y; Yatabe N; Tanaka M; Nakamura M; Inoue M
Oncogene; 2003 Apr; 22(15):2352-60. PubMed ID: 12700670
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation as mechanism of apoptotic resistance development in endometrial cancer patients.
Fialkova V; Vidomanova E; Balharek T; Marcinek J; Kudela E; Hanysova S; Visnovsky J; Dobrota D; Hatok J
Gen Physiol Biophys; 2017 Dec; 36(5):521-529. PubMed ID: 29372685
[TBL] [Abstract][Full Text] [Related]
12. SOX11 hypermethylation as a tumor biomarker in endometrial cancer.
Shan T; Uyar DS; Wang LS; Mutch DG; Huang TH; Rader JS; Sheng X; Huang YW
Biochimie; 2019 Jul; 162():8-14. PubMed ID: 30935961
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment.
Zhou XC; Dowdy SC; Podratz KC; Jiang SW
Gynecol Oncol; 2007 Oct; 107(1):143-53. PubMed ID: 17692907
[TBL] [Abstract][Full Text] [Related]
14. Methylation of hMLH1 in a population-based series of endometrial carcinomas.
Salvesen HB; MacDonald N; Ryan A; Iversen OE; Jacobs IJ; Akslen LA; Das S
Clin Cancer Res; 2000 Sep; 6(9):3607-13. PubMed ID: 10999752
[TBL] [Abstract][Full Text] [Related]
15. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
17. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
18. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer.
Tokunaga E; Oki E; Nishida K; Koga T; Yoshida R; Ikeda K; Kojima A; Egashira A; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2006 May; 97(2):199-203. PubMed ID: 16502017
[TBL] [Abstract][Full Text] [Related]
19. DNA Methylation Machinery in the Endometrium and Endometrial Cancer.
Caplakova V; Babusikova E; Blahovcova E; Balharek T; Zelieskova M; Hatok J
Anticancer Res; 2016 Sep; 36(9):4407-20. PubMed ID: 27630276
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
